Generic drug bill
Executive Summary
Legislation to increase FDA enforcement authority is expected to be introduced on May 15 by Rep. Dingell (D-Mich.), whose House Oversight Subcommittee has investigated the generic drug scandal for nearly two years. The measure will be referred to the Health Subcommittee, chaired by Rep. Waxman (D-Calif.), who will not be a cosponsor. Waxman reportedly is concerned that the bill's sanctions solely target the generic and not the brandname industry and that the HHS Inspector General's enforcement authority might supersede FDA's regarding FD&C Act felony violations.
You may also be interested in...
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.